Your browser doesn't support javascript.
loading
Variation in prognosis and treatment outcome in juvenile myoclonic epilepsy: a Biology of Juvenile Myoclonic Epilepsy Consortium proposal for a practical definition and stratified medicine classifications.
Rubboli, Guido; Beier, Christoph P; Selmer, Kaja K; Syvertsen, Marte; Shakeshaft, Amy; Collingwood, Amber; Hall, Anna; Andrade, Danielle M; Fong, Choong Yi; Gesche, Joanna; Greenberg, David A; Hamandi, Khalid; Lim, Kheng Seang; Ng, Ching Ching; Orsini, Alessandro; Striano, Pasquale; Thomas, Rhys H; Zarubova, Jana; Richardson, Mark P; Strug, Lisa J; Pal, Deb K.
Afiliação
  • Rubboli G; Danish Epilepsy Centre, Filadelfia, Dianalund 4293, Denmark.
  • Beier CP; Institute of Clinical Medicine, University of Copenhagen, Copenhagen 2200, Denmark.
  • Selmer KK; Department of Neurology, Odense University Hospital, Odense 5000, Denmark.
  • Syvertsen M; Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo 0372, Norway.
  • Shakeshaft A; National Centre for Epilepsy, Oslo University Hospital, Oslo 1337, Norway.
  • Collingwood A; Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo 3004, Norway.
  • Hall A; Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Andrade DM; MRC Centre for Neurodevelopmental Disorders, King's College London, London SW1H 9NA, UK.
  • Fong CY; Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Gesche J; Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Greenberg DA; Adult Epilepsy Genetics Program, Krembil Research Institute, University of Toronto, Toronto M5T 0S8, Canada.
  • Hamandi K; Division of Paediatric Neurology, Department of Pediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.
  • Lim KS; Department of Neurology, Odense University Hospital, Odense 5000, Denmark.
  • Ng CC; Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus 43215, USA.
  • Orsini A; Department of Neurology, Cardiff & Vale University Health Board, Cardiff CF14 4XW, UK.
  • Striano P; Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.
  • Thomas RH; Department of Clinical and Experimental Medicine, Pisa University Hospital, Pisa 56126, Italy.
  • Richardson MP; Pediatric Neurology and Muscular Disease Unit, IRCCS Istituto 'G. Gaslini', Genova 16147, Italy.
  • Strug LJ; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova 16132, Italy.
  • Pal DK; Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
Brain Commun ; 5(3): fcad182, 2023.
Article em En | MEDLINE | ID: mdl-37361715
ABSTRACT
Reliable definitions, classifications and prognostic models are the cornerstones of stratified medicine, but none of the current classifications systems in epilepsy address prognostic or outcome issues. Although heterogeneity is widely acknowledged within epilepsy syndromes, the significance of variation in electroclinical features, comorbidities and treatment response, as they relate to diagnostic and prognostic purposes, has not been explored. In this paper, we aim to provide an evidence-based definition of juvenile myoclonic epilepsy showing that with a predefined and limited set of mandatory features, variation in juvenile myoclonic epilepsy phenotype can be exploited for prognostic purposes. Our study is based on clinical data collected by the Biology of Juvenile Myoclonic Epilepsy Consortium augmented by literature data. We review prognosis research on mortality and seizure remission, predictors of antiseizure medication resistance and selected adverse drug events to valproate, levetiracetam and lamotrigine. Based on our analysis, a simplified set of diagnostic criteria for juvenile myoclonic epilepsy includes the following (i) myoclonic jerks as mandatory seizure type; (ii) a circadian timing for myoclonia not mandatory for the diagnosis of juvenile myoclonic epilepsy; (iii) age of onset ranging from 6 to 40 years; (iv) generalized EEG abnormalities; and (v) intelligence conforming to population distribution. We find sufficient evidence to propose a predictive model of antiseizure medication resistance that emphasises (i) absence seizures as the strongest stratifying factor with regard to antiseizure medication resistance or seizure freedom for both sexes and (ii) sex as a major stratifying factor, revealing elevated odds of antiseizure medication resistance that correlates to self-report of catamenial and stress-related factors including sleep deprivation. In women, there are reduced odds of antiseizure medication resistance associated with EEG-measured or self-reported photosensitivity. In conclusion, by applying a simplified set of criteria to define phenotypic variations of juvenile myoclonic epilepsy, our paper proposes an evidence-based definition and prognostic stratification of juvenile myoclonic epilepsy. Further studies in existing data sets of individual patient data would be helpful to replicate our findings, and prospective studies in inception cohorts will contribute to validate them in real-world practice for juvenile myoclonic epilepsy management.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article